July 30, 2008 – BrachySciences will distribute the AnchorSeed for prostate brachytherapy now with a second isotope, TheraSeed palladium-103, offering physicians the option of utilizing AnchorSeed with the two most commonly used isotopes for prostate brachytherapy, iodine-125 and palladium-103.

July 30, 2008 - ImaCor today said it received FDA 510(k) clearance to market the ClariTEE miniaturized transesophageal echocardiography probe and the Zura ultrasound imaging system.

The ClariTEE probe facilitates episodic monitoring of cardiac function. It is a single use device that can remain indwelling for up to 72 hours, allowing intensivists and anesthesiologists to periodically assess cardiac preload and left ventricular systolic function over a prolonged period of time.

July 30, 2008 - Researchers at the Ohio State University Medical Center have designed equipment to provide high resolution images of the heart at peak stress level - a critical stage of testing - that have previously been difficult to obtain using standard testing procedures.

Now superior images of the heart are obtained with a test lasting less than one hour.

The MIM PACS has responded to the need for an affordable storage solution to handle expanding imaging data in radiation oncology from IGRT, gated studies and secondary modalities including PET and MR. MIM Storage Server allows for storage of RT specific formats including RT dose, plan and structs.

MIMvista's MIMfusion serial exam aims to eliminate labor-intensive, multistep processes such as fusion, linking and layouts. With MIMvista’s customizable workflows, any number of exams can reportedly be linked or fused automatically for easy comparison. For example, tumors may be tracked and correlated over multiple time points.

Brachysciences' AnchorSeed for prostate brachytherapy has a design is intended to give existing low dose rate brachytherpay sources enhanced ability to maintain their position within tissue, thereby allowing physicians to confidently place seeds in more strategic and beneficial locations. It is designed to work with Mick Applicators as well as with Pre-Loaded Needles.

July 29, 2008 – Hologic said it has made Third Wave Technologies a wholly owned subsidiary of Hologic.

Third Wave develops and markets molecular diagnostic reagents for a wide variety of DNA and RNA analysis applications based on its proprietary Invader Chemistry, said Hologic. Third Wave currently offers clinical diagnostic product for conditions such as cystic fibrosis, hepatitis C, cardiovascular risk and other diseases. Recently Third Wave submitted pre-market approval (PMA) applications for two human papilloma virus, or HPV, tests to the FDA.

July 29, 2008 - Breathing is a major complication for radiation treatment of lung cancer.

The latest technology plans to tackle the problem by moving the radiation beam in unison with the breath. To help in the tracking, researchers have devised a new algorithm -- similar to one used by the post office -- that can predict where a tumor will be one second beforehand.

July 29, 2008 - Ductal carcinoma in situ (DCIS), the development of cancer cells within the milk ducts of breast tissue, is thought to be a possible precursor of invasive cancer, prompting research to understand its underlying biology-and detect it early.

Now medical physics graduate student Neha Bhooshan of the University of Chicago, her advisor, professor Maryellen Giger, and their colleagues have developed an automated computer image analysis technique to ultimately characterize and diagnose DCIS and other breast carcinomas.

July 29, 2008 - BrainLAB said it received 510(k) clearance for its Monte Carlo Dose Calculation Algorithm, which is already being used at several clinical cooperation sites worldwide.

Subscribe to
© Copyright Wainscot Media. All Rights Reserved.
Subscribe Now